Mario Alberto González

Dr. Mario Alberto González


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2022 in Research in Veterinary Science
Verified
Journal Article
Open access
MGMario Alberto González
Mario Alberto González
RBRafael Barrera-Chacón
Rafael Barrera-Chacón
FPFernando J. Peña
Fernando J. Peña
JFJavier Fernández-Cotrina
Javier Fernández-Cotrina
NRNicolás R. Robles
Nicolás R. Robles
FDFrancisco J. Duque
Francisco J. Duque
Canine leishmaniosis is frequently associated with the development of renal disease. Its pathogenesis is complex and not fully understood. For this reason, this study aimed to describe the urinary proteome, and identify possible new biomarkers in dogs with kidney disease secondary to leishmaniosis. Urine samples were collected from 20 dogs, 5 from healthy dogs, and 15 from stages Leishvet III and IV. Urine samples were analyzed by UHPLC-MS/MS. The data are available via ProteomeXchange with identifier PXD029165. A total of 951 proteins were obtained. After bioinformatic analysis, 93 urinary proteins were altered in the study group. Enrichment analysis performed on these proteins showed an overrepresentation of the complement activation pathway, among others. Finally, 12 discriminant variables were found in dogs with renal disease secondary to leishmaniosis, highlighting C4a anaphylatoxin, apolipoprotein A-I, haptoglobin, leucine-rich alpha-2-glycoprotein 1, and beta-2-microglobulin. This study is the first to describe the urinary proteomics of dogs with renal disease caused by leishmaniosis, and it provides new possible biomarkers for the diagnosis and monitoring of this disease.

22 June 2023 in Research in Veterinary Science
Verified
Journal Article
Open access
MGMario Alberto González
Mario Alberto González
RBRafael Barrera-Chacón
Rafael Barrera-Chacón
FPFernando J. Peña
Fernando J. Peña
SBSilvia Belinchón-Lorenzo
Silvia Belinchón-Lorenzo
NRNicolás R. Robles
Nicolás R. Robles
FDFrancisco J. Duque
Francisco J. Duque
The objective of our study was to search for survival biomarkers (SB) and treatment response monitoring biomarkers (TRMB) in the urinary proteome of dogs with renal disease secondary to canine leishmaniosis (CanL), using UHPLC-MS/MS. The proteomic data are available via ProteomeXchange with identifier PXD042578. Initially, a group of 12 dogs was evaluated and divided into survivors (SG; n = 6) and nonsurvivors (NSG; n = 6). A total of 972 proteins were obtained from the evaluated samples. Then, bioinformatic analysis reduced them to 6 proteins like potential SB increased in the NSG, specifically, Haemoglobin subunit Alpha 1, Complement Factor I, Complement C5, Fibrinogen beta chain (fragment), Peptidase S1 domain-containing protein, and Fibrinogen gamma chain. Afterwards, SG was used to search for TRMB, studying their urine at 0, 30, and 90 days, and 9 proteins that decreased after treatment were obtained: Apolipoprotein E, Cathepsin B, Cystatin B, Cystatin-C-like, Lysozyme, Monocyte differentiation CD14, Pancreatitis-associated precursor protein, Profilin, and Protein FAM3C. Finally, enrichment analysis provided information about the biological mechanisms in which these proteins are involved. In conclusion, this study provides 15 new candidate urinary biomarkers and an improved understanding of the pathogenesis of kidney disease in CanL.

19 February 2021 in Animals
Verified
Journal Article
Open access
PDF file
PNPaloma Nicolas-Barcelo
Paloma Nicolas-Barcelo
MFMartina Facchin
Martina Facchin
FTFernando Martinez Taboada
Fernando Martinez Taboada
RCRafael Barrera Chacón
Rafael Barrera Chacón
JVJosé Ignacio Cristóbal Verdejo
José Ignacio Cristóbal Verdejo
Javier DuqueJavier Duque
Javier Duque
The aim was to evaluate if medetomidine and dexmedetomidine affected arterial ovarian blood flow in dogs. The dogs were randomly assigned to two different groups. In Group 1, medetomidine (10 µg/kg) was administered intramuscularly and, in Group 2, dexmedetomidine (5 µg/kg) was used. After a preliminary exam, arterial blood pressure (BP) was measured and a duplex Doppler ultrasonographic examination of both ovarian arteries was performed. Twenty minutes after the administration of medetomidine or dexmedetomidine, BP and ovarian Doppler ultrasonography were repeated. High quality tracings of ovarian artery flow velocity were obtained in all dogs and Doppler parameters: Peak Systolic Velocity (PSV), End Diastolic Velocity (EDV) and Resistive Index (RI) were measured before and after drug administration in the left (LO) and right (RO) ovaries. PSV and EDV values decreased significantly after drug administration (p < 0.05) compared to the non-sedated values, but no differences were found between the LO and RO (p > 0.05). The RI was not affected by drugs administration in neither of the groups studied (p > 0.05). In conclusion, the administration of medetomidine or dexmedetomidine causes a decrease in blood flow velocity in the ovarian artery and may be a good choice to avoid excessive bleeding prior surgeries in which ovariectomy.

4 November 2026 in Animals
Verified
Journal Article
Open access
PDF file
MGMario Alberto González
Mario Alberto González
RCRafael Barrera Chacón
Rafael Barrera Chacón
JJJoaquín Jiménez-Fragoso
Joaquín Jiménez-Fragoso
BGBeatriz Macías García
Beatriz Macías García
JFJavier Fernández-Cotrina
Javier Fernández-Cotrina
Javier DuqueJavier Duque
Javier Duque
The tolerability and efficacy of treatment with allogeneic adipose-derived mesenchymal stem cells (aAMSCs) were evaluated in dogs with kidney disease secondary to canine leishmaniosis (CanL). In this non-blinded, single-center, 3-month study, twenty dogs received either conventional treatment (CT; n = 10) or conventional treatment plus an intravenous dose of aAMSCs (CT + aAMSCs; n = 10). Efficacy was assessed at days 0, 30, and 90 using plasma and urinary biomarkers. In both groups (CT, n = 6; CT + aAMSCs, n = 7), glomerular filtration rate was estimated by scintigraphy, and urinary proteomics was performed. No serious adverse events were observed, although two dogs experienced transient gastrointestinal events. No significant between-group differences occurred in renal parameters at time points. Intragroup analyses showed significant reductions in uNGAL/c in both groups and UPCR only in CT + aAMSCs. Longitudinal mixed-effects analyses revealed no significant group × time interactions for any of the evaluated variables. Urinary proteomics identified four protein entries with higher abundance in the CT + aAMSCs group at T90, although UMAP showed no separation between groups. A single intravenous aAMSCs dose was well tolerated but provided no renal benefits over conventional treatment. Further studies should evaluate alternative dosing protocols.

22 February 2025 in Research in Veterinary Science
Verified
Journal Article
Open access
MGMario Alberto González
Mario Alberto González
RBRafael Barrera-Chacón
Rafael Barrera-Chacón
JJJoaquín Jiménez
Joaquín Jiménez
SBSilvia Belinchón-Lorenzo
Silvia Belinchón-Lorenzo
MGMaría Gil-Molino
María Gil-Molino
FDFrancisco J. Duque
Francisco J. Duque
This study evaluated the utility of new renal biomarkers in canine leishmaniosis (CanL). A total of 6 healthy dogs (CG) and 22 dogs with CanL (LeishVet stage III or GIII (n = 11) and stage IV or GIV (n = 11)) were included. Plasma creatinine, urea, cystatin C (pCysC), and symmetric dimethylarginine were analyzed. In urine, neutrophil gelatinase-associated lipocalin, retinol-binding protein, Tamm-Horsfall protein, and total protein were measured using their ratios with creatinine (uNGAL/c, uRBP/c, uTHP/c, and UPC, respectively). The estimated glomerular filtration rate (eGFR) was assessed by 99mTc-DTPA scintigraphy. All glomerular biomarkers strongly correlated with eGFR and showed statistically significant differences between CanL stages but not with CG, except for pCysC, which was particularly noteworthy for its statistical significance, instilling confidence in its potential use. All tubular biomarkers presented significant differences between GIV and CG; however, only uNGAL/c and uTHP/c differentiated between GIII and CG. Moreover, none could distinguish between the GIII and GIV groups. These data suggest that the new glomerular biomarkers could help determine stages of renal disease in CanL. uNGAL/c and uTHP/C showed advantages in making an earlier diagnosis. Ultimately, pCysC presented tremendous potential, as it was statistically significant for both uses. This research provides valuable information to understand the behavior of these biomarkers in renal disease secondary to CanL.